Related Experiment Videos
The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas
1Department of Neurosurgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract:
Deregulated p21-Ras function, as a result of mutation, overexpression or growth factor-induced overactivation, contributes to at least 30% of human cancer. This article reviews the potential role of the p21-Ras family of GTPases in the regulation of growth of high-grade gliomas and describes how targeting this oncoprotein clinically may provide a novel strategy to counteract glioma proliferation. The application of strategies directed at selectively opposing the deregulated signal transduction pathway of high-grade gliomas may be of potential therapeutic benefit and may offer a whole new arsenal of antineoplastic agents to be included in the multimodal treatment of these challenging neoplasms.
Insights
Deregulated p21-Ras (Ras) oncoprotein signaling drives human cancers, including high-grade gliomas. Targeting Ras may offer a novel therapeutic strategy to inhibit glioma cell proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Deregulated p21-Ras (Ras) signaling is implicated in over 30% of human cancers.
- Ras GTPases play a critical role in cellular growth and proliferation.
- High-grade gliomas are aggressive brain tumors with limited treatment options.
Purpose of the Study:
- To review the role of the p21-Ras family in high-grade glioma growth.
- To explore the therapeutic potential of targeting Ras in glioma treatment.
- To identify novel antineoplastic strategies for gliomas.
Main Methods:
- Literature review of studies on p21-Ras function in cancer.
- Analysis of signal transduction pathways in high-grade gliomas.
- Evaluation of clinical strategies targeting oncogenic proteins.
Main Results:
- Ras pathway dysregulation is a key driver of high-grade glioma proliferation.
- Targeting Ras offers a promising therapeutic avenue for glioma treatment.
- Modulating Ras signaling may enhance existing multimodal cancer therapies.
Conclusions:
- The p21-Ras pathway is a critical regulator of high-grade glioma growth.
- Targeting Ras represents a novel and potentially effective strategy against gliomas.
- Inclusion of Ras-targeting agents could expand the therapeutic arsenal for challenging gliomas.